Literature DB >> 17720200

Depletion of mitochondrial DNA in leukocytes of patients with poly-Q diseases.

Chin-San Liu1, Wen-Ling Cheng, Shou-Jen Kuo, Jie-Yuan Li, Bing-Wen Soong, Yau-Huei Wei.   

Abstract

Polyglutamine (poly-Q) diseases are late-onset neurodegenerative disorders arising from the expansion of an unstable CAG repeat in the affected gene, which is translated to a tract of glutamine residues. This kind of mutant proteins may be aggregated and accumulated, and thereby enhance cellular oxidative stress. In one of our previous studies (Free Radic. Res. 2003;37:1307-17), we found that alteration in the leukocyte mtDNA content is very sensitive to the level of oxidative stress in blood. Thus, we proposed that leukocyte mtDNA content may be used as a biomarker to predict the severity of clinical manifestation of poly-Q diseases. We recruited 50 healthy subjects and 114 patients with poly-Q diseases, including spinal cerebellar atrophy 2/3, spinal bulbar muscular atrophy, and Huntington chorea. We found that mtDNA in leukocytes was depleted in patients with poly-Q diseases (P<0.05). Moreover, the results showed that patients with lower mtDNA content more frequently manifested multiple-symptom disorders and had high CAG repeat numbers in the mutant genes. In conclusion, we suggest that leukocyte mtDNA content correlates with the length of GAG repeat and may serve as an index of the severity of poly-Q diseases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17720200     DOI: 10.1016/j.jns.2007.07.016

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  10 in total

Review 1.  Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update. II. Hyperkinetic disorders.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2019-06-24       Impact factor: 3.575

2.  Mitochondrial DNA damage is associated with reduced mitochondrial bioenergetics in Huntington's disease.

Authors:  Almas Siddiqui; Sulay Rivera-Sánchez; María del R Castro; Karina Acevedo-Torres; Anand Rane; Carlos A Torres-Ramos; David G Nicholls; Julie K Andersen; Sylvette Ayala-Torres
Journal:  Free Radic Biol Med       Date:  2012-06-16       Impact factor: 7.376

Review 3.  The interrelationship between mitochondrial dysfunction and transcriptional dysregulation in Huntington disease.

Authors:  Youngnam N Jin; Gail V W Johnson
Journal:  J Bioenerg Biomembr       Date:  2010-06       Impact factor: 2.945

Review 4.  Mitochondrial Abnormalities and Synaptic Damage in Huntington's Disease: a Focus on Defective Mitophagy and Mitochondria-Targeted Therapeutics.

Authors:  Neha Sawant; Hallie Morton; Sudhir Kshirsagar; Arubala P Reddy; P Hemachandra Reddy
Journal:  Mol Neurobiol       Date:  2021-09-14       Impact factor: 5.590

Review 5.  Mitochondria and Reactive Oxygen Species in Aging and Age-Related Diseases.

Authors:  Carlotta Giorgi; Saverio Marchi; Ines C M Simoes; Ziyu Ren; Giampaolo Morciano; Mariasole Perrone; Paulina Patalas-Krawczyk; Sabine Borchard; Paulina Jędrak; Karolina Pierzynowska; Jędrzej Szymański; David Q Wang; Piero Portincasa; Grzegorz Węgrzyn; Hans Zischka; Pawel Dobrzyn; Massimo Bonora; Jerzy Duszynski; Alessandro Rimessi; Agnieszka Karkucinska-Wieckowska; Agnieszka Dobrzyn; Gyorgy Szabadkai; Barbara Zavan; Paulo J Oliveira; Vilma A Sardao; Paolo Pinton; Mariusz R Wieckowski
Journal:  Int Rev Cell Mol Biol       Date:  2018-06-22       Impact factor: 6.813

Review 6.  Role of oxidative DNA damage in mitochondrial dysfunction and Huntington's disease pathogenesis.

Authors:  Sylvette Ayala-Peña
Journal:  Free Radic Biol Med       Date:  2013-04-18       Impact factor: 7.376

7.  Differential mtDNA damage patterns in a transgenic mouse model of Machado-Joseph disease (MJD/SCA3).

Authors:  Amanda Ramos; Nadiya Kazachkova; Francisca Silva; Patrícia Maciel; Anabela Silva-Fernandes; Sara Duarte-Silva; Cristina Santos; Manuela Lima
Journal:  J Mol Neurosci       Date:  2014-07-08       Impact factor: 3.444

8.  Mitochondrial DNA levels in Huntington disease leukocytes and dermal fibroblasts.

Authors:  Paulina Jędrak; Magdalena Krygier; Katarzyna Tońska; Małgorzata Drozd; Magdalena Kaliszewska; Ewa Bartnik; Witold Sołtan; Emilia J Sitek; Anna Stanisławska-Sachadyn; Janusz Limon; Jarosław Sławek; Grzegorz Węgrzyn; Sylwia Barańska
Journal:  Metab Brain Dis       Date:  2017-05-16       Impact factor: 3.584

9.  Deterioration of mitochondrial bioenergetics and ultrastructure impairment in skeletal muscle of a transgenic minipig model in the early stages of Huntington's disease.

Authors:  Marie Rodinova; Jana Krizova; Hana Stufkova; Bozena Bohuslavova; Georgina Askeland; Zaneta Dosoudilova; Stefan Juhas; Jana Juhasova; Zdenka Ellederova; Jiri Zeman; Lars Eide; Jan Motlik; Hana Hansikova
Journal:  Dis Model Mech       Date:  2019-07-26       Impact factor: 5.758

Review 10.  A Mitochondria-Associated Oxidative Stress Perspective on Huntington's Disease.

Authors:  Ju Zheng; Joris Winderickx; Vanessa Franssens; Beidong Liu
Journal:  Front Mol Neurosci       Date:  2018-09-19       Impact factor: 5.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.